Cargando…

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?

Detalles Bibliográficos
Autores principales:	Chang, Chia‐Hsuin, Chuang, Lee‐Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031505/ https://www.ncbi.nlm.nih.gov/pubmed/29140602 http://dx.doi.org/10.1111/jdi.12776

Ejemplares similares

Glycated hemoglobin variability and retinopathy progression in type 1 diabetes: Is month‐to‐moth instability a better predictor?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Commentary on risk factors for first and subsequent cardiovascular disease events in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study
por: Lin, Chun‐Hsien, et al.
Publicado: (2020)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
por: Hui, Elaine, et al.
Publicado: (2013)

Microalbuminuria and diabetic retinopathy in type 2 diabetic patients: From risk association to risk prediction
por: Chang, Chia‐Hsuin, et al.
Publicado: (2013)

Fetal exposure to parental smoking and the risk of type 2 diabetes: Are lifestyle‐related factors more important?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2015)

Diurnal Variation of Real-Life Insulin Sensitivity Factor Among Children and Adolescents With Type 1 Diabetes Using Ultra-Long-Acting Basal Insulin Analogs
por: Hegab, Ahmed M.
Publicado: (2022)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2015)

Basal insulin delivery reduction for exercise in type 1 diabetes: finding the sweet spot
por: Thabit, Hood, et al.
Publicado: (2016)

Modern basal insulin analogs: An incomplete story
por: Singh, Awadhesh Kumar, et al.
Publicado: (2014)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
por: Rosenstock, Julio, et al.
Publicado: (2013)

Chewing the fat for better insulin secretion
por: Andrikopoulos, Sofianos
Publicado: (2015)

An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
por: Raslova, Katarina
Publicado: (2010)

Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
por: Kalra, Sanjay
Publicado: (2017)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Effects of medical therapies on retinopathy progression in type 2 diabetes: Is blood pressure control the lower the better?
por: Chang, Chia‐Hsiun, et al.
Publicado: (2011)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Cardiovascular effects of basal insulins
por: Mannucci, Edoardo, et al.
Publicado: (2015)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Zhou, Wenchuan, et al.
Publicado: (2019)

Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2020)

Comparative efficacy and safety of long‐acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta‐analyses
por: Bi, Yan, et al.
Publicado: (2012)

A Real-World Anti-Diabetes Medication Cost Comparison Between Premixed Insulin Analogs and Long-Acting Insulin Analogs in Chinese Patients with Type 2 Diabetes: A Retrospective Database Analysis
por: Gao, Yue, et al.
Publicado: (2018)

Association of Cardiovascular Outcomes and Mortality With Sustained Long-Acting Insulin Only vs Long-Acting Plus Short-Acting Insulin Treatment
por: Schroeder, Emily B., et al.
Publicado: (2021)

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
por: Fordan, Steve, et al.
Publicado: (2009)

Insulin Resistance and Type 2 Diabetes
por: Taylor, Roy
Publicado: (2012)

Effects of Ultra-Long-Acting Insulin Compared to Long-Acting Insulin on Diabetic Ketoacidosis Incidence in Type 1 Diabetes Mellitus Patients
por: Alsofiani, Wafa A, et al.
Publicado: (2022)

Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study
por: Chang, Chia-Hsuin, et al.
Publicado: (2011)

Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis
por: Nørgaard, Kirsten, et al.
Publicado: (2018)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Insulin Basal Dose Is Associated With Better Metabolic Control in Type 1 Diabetes Children and Adolescents
por: Arellano-Llamas, Abril, et al.
Publicado: (2021)

Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
por: Danne, Thomas, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

Diabetic Ketoacidosis Updates: Titratable Insulin Infusions and Long-Acting Insulin Early
por: Kinney, Justin, et al.
Publicado: (2021)

The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs
por: DiBonaventura, Marco, et al.
Publicado: (2014)

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
por: Kim, Ji-Hyun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4ei3780pv96p9hhorqm6mhsjn6